Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine

Blood Cancer Journal

Volumn 3, Issue 11, 2013, Pages

  Cluzeau, T ^a,b   Moreilhon, C ^a   Mounier, N ^a   Karsenti, J M ^a   Gastaud, L ^c   Garnier, G ^d   Re, D ^e   Montagne, N ^f   Gutnecht, J ^g   Auberger, P ^b   Fuzibet, Jg ^a   Cassuto, J P ^a   Raynaud, S ^a,h  

^a PASTEUR HOSPITAL   (France)

^b CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d Service d'hygiène Centre hospitalier Princesse Grâce   (France)

^e Centre Hospitalier de la Fontonne   (France)

^f Centre hospitalier Les Broussailles   (France)

^g Centre Hospitalier Intercommunal   (France)

^h Groupe Francophone des Myelodysplasies   (France)

Author keywords

Azacitidine; Myelodysplastic syndromes; Predictive factor; SNP array

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; COHORT ANALYSIS; COPY NUMBER VARIATION; CYTOGENETICS; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84888422912     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.52     Document Type: Article

References (15)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
2. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403-411.
3. Lamarque M, Raynaud S, Itzykson R, Thepot S, Quesnel B, Dreyfus F et al. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood 2012; 120: 5084-5085.
4. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
5. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008; 111: 1534-1542. (Pubitemid 351213443)
6. Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011; 117: 4552-4560.
7. Tiu RV, Gondek LP, O'Keefe CL, Huh J, Sekeres MA, Elson P et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol 2009; 27: 5219-5226.
8. Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008; 112: 3412-3424.
9. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425. (Pubitemid 44061337)
10. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
11. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 4791-4797.
12. Breems DA, Lowenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica 2011; 96: 491-493.
13. Haferlach C, Alpermann T, Schnittger S, Kern W, Chromik J, Schmid C et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood 2012; 119: 2122-2125.
14. Gondek LP, Tiu R, Haddad AS, O'Keefe CL, Sekeres MA, Theil KS et al. Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. Leukemia 2007; 21: 2058-2061. (Pubitemid 47299988)
15. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 2009; 23: 1605-1613.